Scholarlink

<p>Despite advances in reducing treatment-related toxicities, predictive biomarkers for bleomycin-induced pulmonary toxicity (BPT) remain undefined. Affecting around 10% of classic Hodgkin lymphoma (CHL) and associated with a mortality rate of 10–20%, BPT poses a clinical challenge. This study aimed to characterize the pre-therapeutic nodal tumor microenvironment in CHL patients with and without BPT development. Gene expression profiling (GEP) was performed on diagnostic lymph node biopsies from CHL patients who developed BPT (T-CHL, <i>n</i> = 23) during treatment and those who did not (nT-CHL, <i>n</i> = 47). Differential protein expression of MIF, pSTAT3, LILRB3, and CD206 was further assessed with immunohistochemistry (IHC) in an evaluation cohort (<i>n</i> = 285). GEP revealed T-CHL samples enriched in genes associated with immune regulation and inflammation (<i>STAT3</i>,<i> LILRB3</i>,<i> MIF</i>), fibrosis and tissue remodeling (<i>CD206</i>), and immune signaling and regulation of apoptosis (<i>JAK3</i>) compared with nT-CHL. IHC confirmed higher pSTAT3 (<i>p</i> = 0.001) and CD206 (<i>p</i> = 0.029) expression in T-CHL and lower MIF and LILRB3 expression (both <i>p</i> &lt; 0.001) compared with nT-CHL. These findings suggest that immune and fibrotic signatures in diagnostic biopsies may predict BPT risk. Early identification of high-risk patients could enable personalized treatment approaches that reduce toxicity while maintaining efficacy, positioning tumor microenvironment profiling as a promising strategy for optimizing CHL care.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Lymph node transcriptomic profiles suggest susceptibility to bleomycin-induced pulmonary toxicity in classic hodgkin lymphoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月18日

查看全文
  • Maja Dam Andersen,
  • Marie Hairing Enemark,
  • Kristina Lystlund Lauridsen,
  • Stephen Jacques Hamilton-Dutoit,
  • Jørn Starklint,
  • Francesco d’Amore,
  • Maja Ludvigsen,
  • Peter Kamper

摘要

Despite advances in reducing treatment-related toxicities, predictive biomarkers for bleomycin-induced pulmonary toxicity (BPT) remain undefined. Affecting around 10% of classic Hodgkin lymphoma (CHL) and associated with a mortality rate of 10–20%, BPT poses a clinical challenge. This study aimed to characterize the pre-therapeutic nodal tumor microenvironment in CHL patients with and without BPT development. Gene expression profiling (GEP) was performed on diagnostic lymph node biopsies from CHL patients who developed BPT (T-CHL, n = 23) during treatment and those who did not (nT-CHL, n = 47). Differential protein expression of MIF, pSTAT3, LILRB3, and CD206 was further assessed with immunohistochemistry (IHC) in an evaluation cohort (n = 285). GEP revealed T-CHL samples enriched in genes associated with immune regulation and inflammation (STAT3, LILRB3, MIF), fibrosis and tissue remodeling (CD206), and immune signaling and regulation of apoptosis (JAK3) compared with nT-CHL. IHC confirmed higher pSTAT3 (p = 0.001) and CD206 (p = 0.029) expression in T-CHL and lower MIF and LILRB3 expression (both p < 0.001) compared with nT-CHL. These findings suggest that immune and fibrotic signatures in diagnostic biopsies may predict BPT risk. Early identification of high-risk patients could enable personalized treatment approaches that reduce toxicity while maintaining efficacy, positioning tumor microenvironment profiling as a promising strategy for optimizing CHL care.